Insulin
Drugthe intervention is applied only at the dose of insulin
NCT Number: NCT01754181
The main objective is to assess if the Diabeloop algorithm provides better glycemic control than a "manual" usual algorithm of patients with type 1 diabetes treated by insulin pump during meals, and during activity qualified "moderate" to "severe" by the patients.
The study will be conducted in 18 patients. The investigation centers are: CHSF (for Diabeloop algorithm test during activity), CHU of Grenoble and CHU of Toulouse (for Diabeloop algorithm test during meals.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
University Hospital of Grenoble, Grenoble, France
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
For Grenoble and Toulouse Centers (Prandial algorithm test : MEAL):
For CHSF center (test of algorithm during activity):
Exclusion criteria
the intervention is applied only at the dose of insulin
Time frame: After the end of the tests
Time frame: After the end of the tests
To evaluate the efficacy and safety of prandial algorithm, informed carbohydrate intake by the patient either quantitatively or semi-quantitative, or not informed way.
Time frame: After the end of the tests
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
Other
Development of the Glycemic Control Algorithm, in Prandial and Physical Effort Situations.
Acronym: DiabeloopWP6-0
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05488119
Autoimmune Diseases, Diabetes Mellitus
Stanford, California, United States
View Trial DetailsNCT07696780
Autoimmune Diseases, Diabetes Mellitus
Bern, Canton of Bern, Switzerland
View Trial DetailsNCT05610111
Autoimmune Diseases, Diabetes Mellitus
Charlottesville, Virginia, United States
View Trial DetailsNCT06308549
Autoimmune Diseases, Diabetes Distress
Bad Mergentheim, Baden-Wurttemberg, Germany
View Trial Details